Try Invigor Review

What Try Invigor charges

• NAD+: $340/mo — starting at, per month, as the plan page states it; the consultation and the supplies are included in the figure
• NAD+: $209/mo — starting at, per month, as the plan page states it; the consultation and the supplies are included in the figure
• PT-141: $280/mo — per month, as the plan page states it; the consultation and the supplies are included in the figure
• Sermorelin: $220/mo — starting at; the plan page names no period at all, unlike this seller's NAD+ and PT-141 pages, so this figure carries no term
• Glutathione: $155/mo — starting at; the plan page names no period at all, unlike this seller's NAD+ and PT-141 pages, so this figure carries no term

Three plan pages say per month, two say nothing

The NAD+ injection plan, the oral NAD+ plan and the PT-141 plan each print a figure with the words per month beside it, and each says the consultation and the supplies are included.

The sermorelin plan and the glutathione plan print a figure with no period at all. The same phrase about the consultation and supplies follows, and no billing term follows it.

This site does not fill that gap in. Those two figures are recorded as figures with no term, and the qualifier on each says so, because the seller's other pages prove it knows how to name a period when it wants to.

Twelve of the forty-five sellers compared here carry PT-141 at all, and this seller's PT-141 page is one of the ones that names a period beside the figure.

Named company, named clinical groups, and a domain that moved

The terms name the limited liability company that owns and operates the website, its trading name, and a service address given twice inside the arbitration clauses. California is named as the governing law.

The terms separately name the two medical groups that provide the clinical services, and a third company for laboratory data. Very few sellers here separate those roles by name.

The domain has changed. The old address now redirects to the current one, while the privacy policy, last updated in December 2023, still says the company owns and operates the website at the old address.

This row records the address the site actually serves rather than the one the policy names. Ten of the forty-five sellers compared here name the facility that fills an order; this is one of the thirty-five that do not.

A scope statement worth reading

The footer says the company does not prescribe medication for bodybuilding, athletic performance or cosmetic purposes.

It adds that goals around energy, sexual health or body composition are addressed only when tied to a clinically recognized condition.

That is a narrower scope than most sellers in this market claim for themselves, and it is stated on the page rather than buried in the terms.

It also tells a reader something practical before an intake: a request framed around performance is unlikely to be filled here.

Four compounds, two routes each, no coverage list

NAD+, PT-141, sermorelin and glutathione are the compounds compared here, and each has an injectable plan page and an oral or nasal one.

Only the two NAD+ routes carry figures with a period attached, so the injection-against-oral comparison is cleanest there.

No state coverage list appears on the plan pages or in the privacy policy. Twenty-four of the forty-five sellers here publish none, and this is one of them.

No lab work is described as included in any plan figure, and none of these compounds is an FDA-approved finished drug in the form sold here.

How we verified this

• Read all five plan pages as rendered text in a browser, because a plain fetch is refused by this host for real pages and for a nonsense path alike.
• Confirmed the browser answers a nonsense path with its own not-found page in the same pass, which is what makes the readings above meaningful.
• Recorded the exact wording beside each figure and kept the two pages that name no period separate from the three that do.
• Declined to carry the words per month from the NAD+ and PT-141 pages onto the sermorelin and glutathione figures.
• Took the current domain from the address each request actually resolved to, not from the privacy policy's description of itself.
• Read the terms in full for the operating company, the trading name, the service address, the governing law and the named clinical groups.
• Read the plan pages and the privacy policy for a state coverage sentence and found none.
• Searched the published federal warning-letter record for both the company name and the trading name across the years that record covers, and found no letter to either. That record does not include untitled letters.
• Re-counted the pharmacy-naming, no-state-list and PT-141 claims against the current roster rather than reusing earlier figures.